Newer targeted therapies in psoriasis.
Indian J Dermatol Venereol Leprol
;
2013 Jul; 79(Suppl_7):s47-s52
Article
Dans Anglais
| IMSEAR
| ID: sea-154746
ABSTRACT
Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted due to chronicity of the disease and frequent remissions and relapses. Many available systemic therapies, however, are unsuitable for chronic administration due to the risk of cumulative toxicity. Recent advances in the understanding of the pathophysiology of psoriasis have led to the development of new, genetically engineered, targeted therapies for this disease. These include approaches targeting antigen presentation and co-stimulation, T-cell activation and leukocyte adhesion, action on pro-inflammatory mediators, and modulating the cytokine balance. Although only preliminary data are available so far and there is limited data supporting their use, these trials contribute to a further understanding of the disease and will eventually lead to new therapeutic options for psoriasis.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Psoriasis
/
Protéines de fusion recombinantes
/
Humains
/
Calcitriol
/
Transduction du signal
/
Cytokines
/
Récepteurs aux chimiokines
/
Thérapie moléculaire ciblée
/
Anticorps monoclonaux humanisés
/
Cellules présentatrices d'antigène
langue:
Anglais
Texte intégral:
Indian J Dermatol Venereol Leprol
Année:
2013
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS